6[2]CLARKE CE,GUTTMAN M.Dopamine agonist monotherapy in Parkinson's disease[J].Lancet,2002,360(9347):1767-1769.
7[4]PERACHON S,SCHWARTZ JC,SOKOLOFF P.Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1,D2 and D3 receptors[J].Eur J Pharmacol,1999,366(2-3):293-300.
8[5]KONDO T.Initial therapy for Parkinson's disease:levodopa vs dopamine receptor agonists[J].J Neurol,2002,249 Suppl 2:Ⅱ25-Ⅱ29.